Thermo Fisher eyes Qiagen?
15/11/19 -"Along with the increase in NAV, we have added Coloplast to our peer-based valuation, considering that the Danish MedTech firm’s top-line growth profile has turned comparable to those of Qiagen."
Pages
62
Language
English
Published on
15/11/19
You may also be interested by these reports :
26/04/24
Clariane reported 7.4% growth in its Q1 statutory and organic revenue, with the dynamism being witnessed in all the segments and regions. The ...
24/04/24
Getinge reported a mixed set of results, missing top-line estimates marginally but beating on profit and order intake. Investors cheered the latter, ...
23/04/24
We have factored the 2023 actual figures into our model ahead of the availability of the annual report and more detailed information. The difference ...
22/04/24
Sartorius Stedim reported softer-than-expected Q1 24 numbers, missing the consensus by 5.7%/3.4% on the top line/bottom line, respectively. The ...